Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12, MarketWatch Earnings reports. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $13.33 million. During the same period last year, the business posted ($0.27) EPS. The business’s revenue was down 49.7% compared to the same quarter last year.
Shares of LXRX opened at $7.86 on Thursday. The stock has a market capitalization of $759.48 million, a PE ratio of -6.19 and a beta of 0.70. Lexicon Pharmaceuticals has a one year low of $4.26 and a one year high of $13.97.
Several institutional investors and hedge funds have recently modified their holdings of LXRX. Clearbridge Investments LLC grew its stake in shares of Lexicon Pharmaceuticals by 974,268.4% in the 3rd quarter. Clearbridge Investments LLC now owns 1,295,910 shares of the biopharmaceutical company’s stock valued at $13,827,000 after buying an additional 1,295,777 shares during the period. D. E. Shaw & Co. Inc. grew its stake in shares of Lexicon Pharmaceuticals by 181.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock valued at $1,783,000 after buying an additional 173,096 shares during the period. Norges Bank acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $1,005,000. First Trust Advisors LP acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at about $1,525,000. Finally, Candriam Luxembourg S.C.A. grew its stake in shares of Lexicon Pharmaceuticals by 36.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 509,000 shares of the biopharmaceutical company’s stock valued at $5,431,000 after buying an additional 137,000 shares during the period. Institutional investors own 99.34% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals (LXRX) Announces Earnings Results” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/4220171/lexicon-pharmaceuticals-lxrx-announces-earnings-results.html.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: NASDAQ Stock Market Explained
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.